Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis
Qiaofeng Zhong,Longfeng Zhang,Lin Wu,Jun Zhao,Jianguo Sun,Yong Fang,Jin Zhou,Qian Chu,Yihong Shen,Zhenzhou Yang,Lijin Chen,Meijuan Huang,Xiaoyan Lin,Zhenhua Liu,Peng Shen,Zhijie Wang,Xin Wang,Huijuan Wang,Chengbo Han,Anwen Liu,Hongmei Zhang,Feng Ye,Wen Gao,Fang Wu,Zhengbo Song,Shengchi Chen,Chengzhi Zhou,Dingzhi Huang,Qiuyu Zhang,Xinlong Zheng,Xiaobin Zheng,Qian Miao,Kan Jiang,Zihua Zou,Yiquan Xu,Shiwen Wu,Haibo Wang,Yaping Hong,Tao Lu,Chao Li,Cheng Huang,Chuanben Chen,Gen Lin
DOI: https://doi.org/10.1177/17588359241266188
2024-01-01
Therapeutic Advances in Medical Oncology
Abstract:Background: Tumor necrosis (TN) is a common feature in lung squamous cell carcinoma (LSCC), which could provide useful predictive and prognostic information. Objectives: This study aimed to investigate the effect of pretreatment pulmonary TN (PTN) on the prognosis of first-line anti-programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) inhibitor in advanced LSCC. Design: We conducted a retrospective study to analyze the association between the presence of PTN and clinical outcomes in advanced LSCC patients treated with anti-PD-1/PD-L1 inhibitors. Methods: Data from 240 eligible patients were collected from 27 hospitals across China between 2016 and 2020. The presence of PTN was assessed using contrast-enhanced chest computed tomography (CT) imaging at baseline. We utilized the Cox proportional-hazards regression model to analyze the association between PTN and clinical outcomes. In addition, to account for potential confounding factors and ensure comparability between groups, we employed propensity score-matching (PSM) analysis. Results: In the overall patient cohort, the presence of PTN was 39.6%. The median follow-up duration was 20.3 months. The positive PTN group exhibited a notably inferior median progression-free survival (PFS; 6.5 months vs 8.6 months, p = 0.012) compared to the negative PTN group. Within the Cox proportional-hazards regression model, PTN emerged as an independent predictor of unfavorable PFS (hazard ratio (HR) = 1.354, 95% confidence interval (CI): 1.002–1.830, p = 0.049). After PSM, the median PFS for the positive PTN group (6.5 months vs 8.0 months, p = 0.027) remained worse than that of the negative PTN group. Multivariate analyses also further underscored that the presence of PTN independently posed a risk for shorter PFS (HR = 1.494, 95% CI: 1.056–2.112, p = 0.023). However, no statistically significant difference in overall survival was observed between the two groups. Conclusion: Our study suggests that the presence of PTN on baseline contrast-enhanced chest CT is a potential negative prognostic imaging biomarker for the outcome of anti-PD-1/PD-L1 inhibitor therapy in advanced LSCC. Further studies are warranted to validate these findings and explore the underlying mechanisms.
oncology